Systematic review / meta-analysis / 2024
Semaglutide and tirzepatide led to substantial reductions in body weight and waist circumference in people with obesity without diabetes.
A systematic review and meta-analysis of seven randomized controlled trials (n = 5,140) evaluated once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg in individuals with obesity without diabetes. Across the therapies, the placebo-subtracted difference in body weight was -15.0% (-12.9% for semaglutide and -19.2% for tirzepatide), and the reduction in waist circumference was -11.4 cm (-9.7 cm for semaglutide and -14.6 cm for tirzepatide). Adverse events were mainly mild-to-moderate, mostly gastrointestinal, and more common during dose titration before leveling off.
- Study type
- Systematic review and meta-analysis of randomized controlled trials
- Who was studied
- 5,140 people with obesity without diabetes across 7 randomized controlled trials
- What was measured
- Placebo-subtracted differences in body weight, waist circumference, and safety
THE PAPER
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.
Müllertz ALO, Sandsdal RM, Jensen SBK, Torekov SS. Obes Rev, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.